CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

By M. Burr, C. Sparbier, Yih-Chih Chan, J. Williamson, K. Woods, P. Beavis, E. Lam, M. Henderson, Charles C. Bell, Sabine Stolzenburg and 14 more. Nature, 2017

837 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/5fe6cd5a9cee52bfd1bf9554d0f361c2b31e705a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Hung
2. Charles Swanton
3. J. Hsu
4. Chia‐Wei Li
5. Jong-Ho Cha
6. M. Hellmann
7. Nicholas McGranahan
8. J. Wolchok

In Oncology

1. Nicholas McGranahan
2. M. Hellmann
3. J. Wolchok
4. M. Callahan
5. M. Hung
6. Charles Swanton
7. J. Hsu
8. Chia‐Wei Li

Citations in the corpus

• Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures (2019, background): “Preclinical (64) and clinical (65) reports have described associations between individual altered genes and response or resistance to immune-checkpoint blockade.”
• Mechanisms controlling PD-L1 expression in cancer (2019, background): “Moreover, CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) prevents PD-L1 from entering the recycling endosomes by blocking STUB1 and PD-L1 interaction (Burr et al., 2017; Mezzadra et al., 2017).”
• Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory (2019, background): “Given that PD-L1 is endocytosed from the surface of cells (Burr et al., 2017; Mezzadra et al., 2017), we hypothesized that PD-L1 is being specifically secreted in the form of exosomes.”
• Regulatory mechanisms of PD-1/PD-L1 in cancers (2024, background): “The binding of CMTM6 to PD-L1 inhibits the lysosomal degradation of PD-L1, after knocking out CMTM6, the E3 ubiquitin ligase STUB1 induces PD-L1 polyubiquitination in the circulating endosomes, thereby degrading it via the lysosomal pathway [302].”
• Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer (2018, background): “, 2016) and pre-clinical reports usingCRISPR/Cas9 screening (Burr et al., 2017;Manguso et al., 2017; Patel et al., 2017) have begun to elucidate genes in both tumors and T cells that are critical to response or resistance to immunotherapy.”